预防性治疗成人偏头痛的新药:erenumab
|
摘要
erenumab是一种新型成人偏头痛预防性治疗药物,是首个批准上市的降钙素基因相关肽(CGRP)受体拮抗剂,仅限于皮下注射。药物通过靶向结合并拮抗CGRP受体起到治疗偏头痛的作用。临床试验显示,在患有发作性或慢性偏头痛患者中,每月皮下注射erenumab 70 mg或140 mg可显著降低月平均偏头痛日数,证明erenumab可预防治疗偏头痛。
Erenumab is a new drug which is indicated for preventive treatment of migraine in adults.Erenumab is the first approved calcitonin gene-related peptide (CGRP) receptor antagonist which is injected subcutaneously only. Erenumab binds to the CGRP receptor and antagonizes CGRP receptor function. Clinical trials showed that, in patients with episodic or chronic migraine, erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced the number of monthly migraine days, providing evidence that erenumab could be a potential therapy for migraine prevention.
Erenumab is a new drug which is indicated for preventive treatment of migraine in adults.Erenumab is the first approved calcitonin gene-related peptide (CGRP) receptor antagonist which is injected subcutaneously only. Erenumab binds to the CGRP receptor and antagonizes CGRP receptor function. Clinical trials showed that, in patients with episodic or chronic migraine, erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced the number of monthly migraine days, providing evidence that erenumab could be a potential therapy for migraine prevention.
引文
[1]LIPTON RB,STEWART WF,DIAMOND S,et al.Prevalence and burden of migraine in the United States:data from the American Migraine StudyⅡ[J].Headache,2001,41(7):646-657.
[2]LIPTON RB,STEWART WF,SIMON D.Medical consultation for migraine:results from the American Migraine Study[J].Headache,1998,38(2):87-96.
[3]VILLALON CM,OLESEN J.The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs[J].Pharmacol Ther,2009,124(3):309-323.
[4]WILLIAMSON DJ,HARGREAVES RJ.Neurogenic inflammation in the context of migraine[J].Microsc Res Tech,2001,53(3):167-178.
[5]EDVINSSON L,HAANES KA,WARFVINGE K,et al.CGRPas the target of new migraine therapies-successful translation from bench to clinic[J].Nat Rev Neurol,2018,14(6):338-350.
[6]EDVINSSON L.CGRP blockers in migraine therapy:where do they act?[J].Br J Pharmacol,2008,155(7):967-969.
[7]CAMERON C,KELLY S,HSIEH SC,et al.Triptans in the acute treatment of migraine:a systematic review and network meta-analysis[J].Headache,2015,55 Suppl 4:221-235.
[8]FDA.Full prescribing information:AimovigTM[EB/OL].(2018-05-17)[2018-07-02].https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf.
[9]SHI L,LEHTO SG,ZHU DX,et al.Pharmacologic characterization of AMG334,a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor[J].J Pharmacol Exp Ther,2016,356(1):223-231.
[10]VU T,MA P,CHEN JS,et al.Pharmacokinetic-pharmacodynamic relationship of erenumab(AMG 334)and capsaicin-induced dermal blood flow in healthy and migraine subjects[J].Pharm Res,2017,34(9):1784-1795.
[11]GOADSBY PJ,REUTER U,HALLSTROM Y,et al.A controlled trial of erenumab for episodic migraine[J].N Engl J Med,2017,377(22):2123-2132.
[12]DODICK DW,ASHINA M,BRANDES JL,et al.ARISE:a phase 3 randomised trial of erenumab for episodic migraine[J].2018,38(6):1026-1037.
[13]TEPPER S,ASHINA M,REUTER U,et al.Safety and efficacy of erenumab for preventive treatment of chronic migraine:a randomised,double-blind,placebo-controlled phase 2 trial[J].Lancet Neurol,2017,16(6):425-434.
[2]LIPTON RB,STEWART WF,SIMON D.Medical consultation for migraine:results from the American Migraine Study[J].Headache,1998,38(2):87-96.
[3]VILLALON CM,OLESEN J.The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs[J].Pharmacol Ther,2009,124(3):309-323.
[4]WILLIAMSON DJ,HARGREAVES RJ.Neurogenic inflammation in the context of migraine[J].Microsc Res Tech,2001,53(3):167-178.
[5]EDVINSSON L,HAANES KA,WARFVINGE K,et al.CGRPas the target of new migraine therapies-successful translation from bench to clinic[J].Nat Rev Neurol,2018,14(6):338-350.
[6]EDVINSSON L.CGRP blockers in migraine therapy:where do they act?[J].Br J Pharmacol,2008,155(7):967-969.
[7]CAMERON C,KELLY S,HSIEH SC,et al.Triptans in the acute treatment of migraine:a systematic review and network meta-analysis[J].Headache,2015,55 Suppl 4:221-235.
[8]FDA.Full prescribing information:AimovigTM[EB/OL].(2018-05-17)[2018-07-02].https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf.
[9]SHI L,LEHTO SG,ZHU DX,et al.Pharmacologic characterization of AMG334,a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor[J].J Pharmacol Exp Ther,2016,356(1):223-231.
[10]VU T,MA P,CHEN JS,et al.Pharmacokinetic-pharmacodynamic relationship of erenumab(AMG 334)and capsaicin-induced dermal blood flow in healthy and migraine subjects[J].Pharm Res,2017,34(9):1784-1795.
[11]GOADSBY PJ,REUTER U,HALLSTROM Y,et al.A controlled trial of erenumab for episodic migraine[J].N Engl J Med,2017,377(22):2123-2132.
[12]DODICK DW,ASHINA M,BRANDES JL,et al.ARISE:a phase 3 randomised trial of erenumab for episodic migraine[J].2018,38(6):1026-1037.
[13]TEPPER S,ASHINA M,REUTER U,et al.Safety and efficacy of erenumab for preventive treatment of chronic migraine:a randomised,double-blind,placebo-controlled phase 2 trial[J].Lancet Neurol,2017,16(6):425-434.